These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

966 related articles for article (PubMed ID: 28846956)

  • 21. POLE somatic mutations in advanced colorectal cancer.
    Guerra J; Pinto C; Pinto D; Pinheiro M; Silva R; Peixoto A; Rocha P; Veiga I; Santos C; Santos R; Cabreira V; Lopes P; Henrique R; Teixeira MR
    Cancer Med; 2017 Dec; 6(12):2966-2971. PubMed ID: 29072370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy.
    Zhao P; Li L; Jiang X; Li Q
    J Hematol Oncol; 2019 May; 12(1):54. PubMed ID: 31151482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours.
    Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI
    J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.
    Germano G; Lamba S; Rospo G; Barault L; Magrì A; Maione F; Russo M; Crisafulli G; Bartolini A; Lerda G; Siravegna G; Mussolin B; Frapolli R; Montone M; Morano F; de Braud F; Amirouchene-Angelozzi N; Marsoni S; D'Incalci M; Orlandi A; Giraudo E; Sartore-Bianchi A; Siena S; Pietrantonio F; Di Nicolantonio F; Bardelli A
    Nature; 2017 Dec; 552(7683):116-120. PubMed ID: 29186113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comprehensive analysis of POLE/POLD1 genomic alterations in colorectal cancer.
    Mosalem O; Coston TW; Imperial R; Mauer E; Thompson C; Yilma B; Bekaii-Saab TS; Stoppler MC; Starr JS
    Oncologist; 2024 Sep; 29(9):e1224-e1227. PubMed ID: 38776551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune Activation in Mismatch Repair-Deficient Carcinogenesis: More Than Just Mutational Rate.
    Willis JA; Reyes-Uribe L; Chang K; Lipkin SM; Vilar E
    Clin Cancer Res; 2020 Jan; 26(1):11-17. PubMed ID: 31383734
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors.
    Mestrallet G; Brown M; Bozkus CC; Bhardwaj N
    Front Immunol; 2023; 14():1210164. PubMed ID: 37492581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.
    Cohen R; Buhard O; Cervera P; Hain E; Dumont S; Bardier A; Bachet JB; Gornet JM; Lopez-Trabada D; Dumont S; Kaci R; Bertheau P; Renaud F; Bibeau F; Parc Y; Vernerey D; Duval A; Svrcek M; André T
    Eur J Cancer; 2017 Nov; 86():266-274. PubMed ID: 29055842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.
    Domingo E; Freeman-Mills L; Rayner E; Glaire M; Briggs S; Vermeulen L; Fessler E; Medema JP; Boot A; Morreau H; van Wezel T; Liefers GJ; Lothe RA; Danielsen SA; Sveen A; Nesbakken A; Zlobec I; Lugli A; Koelzer VH; Berger MD; Castellví-Bel S; Muñoz J; ; de Bruyn M; Nijman HW; Novelli M; Lawson K; Oukrif D; Frangou E; Dutton P; Tejpar S; Delorenzi M; Kerr R; Kerr D; Tomlinson I; Church DN
    Lancet Gastroenterol Hepatol; 2016 Nov; 1(3):207-216. PubMed ID: 28404093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
    Eso Y; Shimizu T; Takeda H; Takai A; Marusawa H
    J Gastroenterol; 2020 Jan; 55(1):15-26. PubMed ID: 31494725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.
    Li HD; Lu C; Zhang H; Hu Q; Zhang J; Cuevas IC; Sahoo SS; Aguilar M; Maurais EG; Zhang S; Wang X; Akbay EA; Li GM; Li B; Koduru P; Ly P; Fu YX; Castrillon DH
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32699191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent genetic alterations in DNA polymerase proofreading and mismatch repair in human colorectal cancer.
    Yoshida R; Miyashita K; Inoue M; Shimamoto A; Yan Z; Egashira A; Oki E; Kakeji Y; Oda S; Maehara Y
    Eur J Hum Genet; 2011 Mar; 19(3):320-5. PubMed ID: 21157497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy.
    Chang L; Chang M; Chang HM; Chang F
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):e15-e21. PubMed ID: 28877075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in personalized neoantigen vaccines for cancer immunotherapy.
    Sun C; Xu S
    Biosci Trends; 2020 Nov; 14(5):349-353. PubMed ID: 32908077
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges.
    Link JT; Overman MJ
    Cancer J; 2016; 22(3):190-5. PubMed ID: 27341597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer.
    Picard E; Verschoor CP; Ma GW; Pawelec G
    Front Immunol; 2020; 11():369. PubMed ID: 32210966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical and Molecular Characterization of
    Garmezy B; Gheeya J; Lin HY; Huang Y; Kim T; Jiang X; Thein KZ; Pilié PG; Zeineddine F; Wang W; Shaw KR; Rodon J; Shen JP; Yuan Y; Meric-Bernstam F; Chen K; Yap TA
    JCO Precis Oncol; 2022 Feb; 6():e2100267. PubMed ID: 35108036
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoantigens in cancer immunotherapy.
    Schumacher TN; Schreiber RD
    Science; 2015 Apr; 348(6230):69-74. PubMed ID: 25838375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Germline
    Lindsay H; Scollon S; Reuther J; Voicu H; Rednam SP; Lin FY; Fisher KE; Chintagumpala M; Adesina AM; Parsons DW; Plon SE; Roy A
    Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31624068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy.
    Viale G; Trapani D; Curigliano G
    Biomed Res Int; 2017; 2017():4719194. PubMed ID: 28770222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.